COG Stock Overview
A neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cambridge Cognition Holdings Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.28 |
| 52 Week High | UK£0.60 |
| 52 Week Low | UK£0.26 |
| Beta | 0.81 |
| 11 Month Change | 1.79% |
| 3 Month Change | -33.72% |
| 1 Year Change | -47.71% |
| 33 Year Change | -76.92% |
| 5 Year Change | -1.72% |
| Change since IPO | -64.38% |
Recent News & Updates
Shareholder Returns
| COG | GB Healthcare Services | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.0% | -0.3% |
| 1Y | -47.7% | 25.2% | 6.1% |
Return vs Industry: COG underperformed the UK Healthcare Services industry which returned 25.2% over the past year.
Return vs Market: COG underperformed the UK Market which returned 6.1% over the past year.
Price Volatility
| COG volatility | |
|---|---|
| COG Average Weekly Movement | 6.2% |
| Healthcare Services Industry Average Movement | 6.2% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: COG has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: COG's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 119 | Rob Baker | www.cambridgecognition.com |
Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval. It also offers eCOA, a data management tool for clinical scales which supports questionnaires and issue resolutions; and provides cognitive kit for detecting fluctuations in brain health.
Cambridge Cognition Holdings Plc Fundamentals Summary
| COG fundamental statistics | |
|---|---|
| Market cap | UK£11.87m |
| Earnings (TTM) | -UK£1.32m |
| Revenue (TTM) | UK£13.08m |
0.9x
P/S Ratio-9.0x
P/E RatioIs COG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COG income statement (TTM) | |
|---|---|
| Revenue | UK£13.08m |
| Cost of Revenue | UK£2.52m |
| Gross Profit | UK£10.56m |
| Other Expenses | UK£11.88m |
| Earnings | -UK£1.32m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.032 |
| Gross Margin | 80.77% |
| Net Profit Margin | -10.07% |
| Debt/Equity Ratio | 92.5% |
How did COG perform over the long term?
See historical performance and comparison